Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer
We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria. 18 with benign urological conditions and 20 healthy subjects....
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2001, Vol.32 (3), p.367-370 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 370 |
|---|---|
| container_issue | 3 |
| container_start_page | 367 |
| container_title | International urology and nephrology |
| container_volume | 32 |
| creator | Oge, O Atsü, N Kendi, S Ozen, H |
| description | We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria. 18 with benign urological conditions and 20 healthy subjects. Overall sensitivity and specificity of NMP22 with reference value of 10 U/ml was 72 and 73%, respectively. Sensitivity for pT1 and pT2 tumors was 83%, whereas that for pTa tumors was 55%. When the test was determined before and after transurethral resection (TUR) of bladder tumor, it was shown that the TUR effected the NMP22 level. Urinary NMP22 was highly sensitive for high-risk bladder cancer. However, the sensitivity of the test is somewhat lower in low grade and stage tumors. Additionally, the effect of previous resection limits its value in the follow up of patients with superficial tumors. The larger series with longer follow up may lead us to determine the time to neglect the effect of TUR on NMP22 and the test kit should be upgraded by the manufacturer to exclude the false positive results due to inflammatory conditions. |
| doi_str_mv | 10.1023/A:1017509418440 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71210628</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>386448801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c195t-f6643d28404abd0f11fb79b82579bac3ea6a1fb52d9523670dbfc78fbb054b113</originalsourceid><addsrcrecordid>eNpdkDlPw0AQhVcIREKgpkMrCgSFYWYPe00XReGQwlFAbe1l4eDYYW0j-PcsImloZqR5n57eG0KOES4RGL-aXiNgJiEXqISAHTJGmfGESSV2yRg4YIIp4yNy0HVLAMgVwD4ZIUrFuRRj4uafuh50X7UNbUvaDLb2OtCV7kP1Rdeh7X3VUMbo-ePDM2MXVHdU035Ytb9QePeBRr1_89T53tutj6m1c1GzurE-HJK9UtedP9rsCXm9mb_M7pLF0-39bLpILOayT8o0FdwxJUBo46BELE2WG8VknNpyr1MdT5K5XDKeZuBMaTNVGgNSGEQ-IWd_vjH3x-C7vlhVnfV1rRvfDl2RIUNImYrg6T9w2Q6hidkKhikqJWOSCTnZQINZeVesQxUbfxfb5_EfRl5vGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216188564</pqid></control><display><type>article</type><title>Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Oge, O ; Atsü, N ; Kendi, S ; Ozen, H</creator><creatorcontrib>Oge, O ; Atsü, N ; Kendi, S ; Ozen, H</creatorcontrib><description>We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria. 18 with benign urological conditions and 20 healthy subjects. Overall sensitivity and specificity of NMP22 with reference value of 10 U/ml was 72 and 73%, respectively. Sensitivity for pT1 and pT2 tumors was 83%, whereas that for pTa tumors was 55%. When the test was determined before and after transurethral resection (TUR) of bladder tumor, it was shown that the TUR effected the NMP22 level. Urinary NMP22 was highly sensitive for high-risk bladder cancer. However, the sensitivity of the test is somewhat lower in low grade and stage tumors. Additionally, the effect of previous resection limits its value in the follow up of patients with superficial tumors. The larger series with longer follow up may lead us to determine the time to neglect the effect of TUR on NMP22 and the test kit should be upgraded by the manufacturer to exclude the false positive results due to inflammatory conditions.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1023/A:1017509418440</identifier><identifier>PMID: 11583354</identifier><identifier>CODEN: IURNAE</identifier><language>eng</language><publisher>Netherlands: Springer Nature B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor ; Bladder cancer ; Carcinoma, Transitional Cell - diagnosis ; Carcinoma, Transitional Cell - pathology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Nuclear Proteins - urine ; Prospective Studies ; Reference Values ; Sensitivity and Specificity ; Urinary Bladder Neoplasms - diagnosis ; Urinary Bladder Neoplasms - pathology</subject><ispartof>International urology and nephrology, 2001, Vol.32 (3), p.367-370</ispartof><rights>Copyright (c) 2001 Kluwer Academic Publishers</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c195t-f6643d28404abd0f11fb79b82579bac3ea6a1fb52d9523670dbfc78fbb054b113</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11583354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oge, O</creatorcontrib><creatorcontrib>Atsü, N</creatorcontrib><creatorcontrib>Kendi, S</creatorcontrib><creatorcontrib>Ozen, H</creatorcontrib><title>Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><description>We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria. 18 with benign urological conditions and 20 healthy subjects. Overall sensitivity and specificity of NMP22 with reference value of 10 U/ml was 72 and 73%, respectively. Sensitivity for pT1 and pT2 tumors was 83%, whereas that for pTa tumors was 55%. When the test was determined before and after transurethral resection (TUR) of bladder tumor, it was shown that the TUR effected the NMP22 level. Urinary NMP22 was highly sensitive for high-risk bladder cancer. However, the sensitivity of the test is somewhat lower in low grade and stage tumors. Additionally, the effect of previous resection limits its value in the follow up of patients with superficial tumors. The larger series with longer follow up may lead us to determine the time to neglect the effect of TUR on NMP22 and the test kit should be upgraded by the manufacturer to exclude the false positive results due to inflammatory conditions.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor</subject><subject>Bladder cancer</subject><subject>Carcinoma, Transitional Cell - diagnosis</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Nuclear Proteins - urine</subject><subject>Prospective Studies</subject><subject>Reference Values</subject><subject>Sensitivity and Specificity</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Urinary Bladder Neoplasms - pathology</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkDlPw0AQhVcIREKgpkMrCgSFYWYPe00XReGQwlFAbe1l4eDYYW0j-PcsImloZqR5n57eG0KOES4RGL-aXiNgJiEXqISAHTJGmfGESSV2yRg4YIIp4yNy0HVLAMgVwD4ZIUrFuRRj4uafuh50X7UNbUvaDLb2OtCV7kP1Rdeh7X3VUMbo-ePDM2MXVHdU035Ytb9QePeBRr1_89T53tutj6m1c1GzurE-HJK9UtedP9rsCXm9mb_M7pLF0-39bLpILOayT8o0FdwxJUBo46BELE2WG8VknNpyr1MdT5K5XDKeZuBMaTNVGgNSGEQ-IWd_vjH3x-C7vlhVnfV1rRvfDl2RIUNImYrg6T9w2Q6hidkKhikqJWOSCTnZQINZeVesQxUbfxfb5_EfRl5vGA</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>Oge, O</creator><creator>Atsü, N</creator><creator>Kendi, S</creator><creator>Ozen, H</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2001</creationdate><title>Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer</title><author>Oge, O ; Atsü, N ; Kendi, S ; Ozen, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c195t-f6643d28404abd0f11fb79b82579bac3ea6a1fb52d9523670dbfc78fbb054b113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor</topic><topic>Bladder cancer</topic><topic>Carcinoma, Transitional Cell - diagnosis</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Nuclear Proteins - urine</topic><topic>Prospective Studies</topic><topic>Reference Values</topic><topic>Sensitivity and Specificity</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Urinary Bladder Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oge, O</creatorcontrib><creatorcontrib>Atsü, N</creatorcontrib><creatorcontrib>Kendi, S</creatorcontrib><creatorcontrib>Ozen, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oge, O</au><au>Atsü, N</au><au>Kendi, S</au><au>Ozen, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer</atitle><jtitle>International urology and nephrology</jtitle><addtitle>Int Urol Nephrol</addtitle><date>2001</date><risdate>2001</risdate><volume>32</volume><issue>3</issue><spage>367</spage><epage>370</epage><pages>367-370</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><coden>IURNAE</coden><abstract>We prospectively evaluated the performance of urinary NMP22 test in the detection of transitional carcinoma (TCC) of the bladder. Urine samples were obtained from 39 patients with known bladder cancer, 37 patients with primary hematuria. 18 with benign urological conditions and 20 healthy subjects. Overall sensitivity and specificity of NMP22 with reference value of 10 U/ml was 72 and 73%, respectively. Sensitivity for pT1 and pT2 tumors was 83%, whereas that for pTa tumors was 55%. When the test was determined before and after transurethral resection (TUR) of bladder tumor, it was shown that the TUR effected the NMP22 level. Urinary NMP22 was highly sensitive for high-risk bladder cancer. However, the sensitivity of the test is somewhat lower in low grade and stage tumors. Additionally, the effect of previous resection limits its value in the follow up of patients with superficial tumors. The larger series with longer follow up may lead us to determine the time to neglect the effect of TUR on NMP22 and the test kit should be upgraded by the manufacturer to exclude the false positive results due to inflammatory conditions.</abstract><cop>Netherlands</cop><pub>Springer Nature B.V</pub><pmid>11583354</pmid><doi>10.1023/A:1017509418440</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2001, Vol.32 (3), p.367-370 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71210628 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Biomarkers, Tumor Bladder cancer Carcinoma, Transitional Cell - diagnosis Carcinoma, Transitional Cell - pathology Female Humans Male Middle Aged Neoplasm Staging Nuclear Proteins - urine Prospective Studies Reference Values Sensitivity and Specificity Urinary Bladder Neoplasms - diagnosis Urinary Bladder Neoplasms - pathology |
| title | Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T14%3A29%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20nuclear%20matrix%20protein%2022%20(NMP22)%20as%20a%20tumor%20marker%20in%20the%20detection%20of%20bladder%20cancer&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Oge,%20O&rft.date=2001&rft.volume=32&rft.issue=3&rft.spage=367&rft.epage=370&rft.pages=367-370&rft.issn=0301-1623&rft.eissn=1573-2584&rft.coden=IURNAE&rft_id=info:doi/10.1023/A:1017509418440&rft_dat=%3Cproquest_pubme%3E386448801%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216188564&rft_id=info:pmid/11583354&rfr_iscdi=true |